392 related articles for article (PubMed ID: 22571450)
1. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.
Klassen LJ; Bilkey TS; Katzman MA; Chokka P
Curr Drug Abuse Rev; 2012 Sep; 5(3):190-8. PubMed ID: 22571450
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.
Simon N; Rolland B; Karila L
Curr Pharm Des; 2015; 21(23):3359-66. PubMed ID: 26088112
[TBL] [Abstract][Full Text] [Related]
3. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
Kollins SH
Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
[TBL] [Abstract][Full Text] [Related]
4. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
5. [Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?].
Paslakis G; Kiefer F; Diehl A; Alm B; Sobanski E
Nervenarzt; 2010 Mar; 81(3):277-88. PubMed ID: 20108084
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.
Tamm L; Trello-Rishel K; Riggs P; Nakonezny PA; Acosta M; Bailey G; Winhusen T
J Subst Abuse Treat; 2013 Feb; 44(2):224-30. PubMed ID: 22889694
[TBL] [Abstract][Full Text] [Related]
7. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
[TBL] [Abstract][Full Text] [Related]
8. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
Szobot CM; Rohde LA; Katz B; Ruaro P; Schaefer T; Walcher M; Bukstein O; Pechansky F
Braz J Med Biol Res; 2008 Mar; 41(3):250-7. PubMed ID: 18327433
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
Pérez de los Cobos J; Siñol N; Pérez V; Trujols J
Br J Clin Pharmacol; 2014 Feb; 77(2):337-56. PubMed ID: 23216449
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
Goldman LS; Genel M; Bezman RJ; Slanetz PJ
JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
[TBL] [Abstract][Full Text] [Related]
11. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
[TBL] [Abstract][Full Text] [Related]
12. Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.
Szobot CM; Shih MC; Schaefer T; Júnior N; Hoexter MQ; Fu YK; Pechansky F; Bressan RA; Rohde LA
Neuroimage; 2008 Apr; 40(3):1195-201. PubMed ID: 18282769
[TBL] [Abstract][Full Text] [Related]
13. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
Dalsgaard S; Mortensen PB; Frydenberg M; Thomsen PH
Addict Behav; 2014 Jan; 39(1):325-8. PubMed ID: 24090624
[TBL] [Abstract][Full Text] [Related]
14. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate doses in Attention Deficit/Hyperactivity Disorder and comorbid substance use disorders.
Skoglund C; Brandt L; D'Onofrio B; Larsson H; Franck J
Eur Neuropsychopharmacol; 2017 Nov; 27(11):1144-1152. PubMed ID: 28935267
[TBL] [Abstract][Full Text] [Related]
16. Attention deficit hyperactivity disorder and substance use disorders.
Szobot CM; Bukstein O
Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):309-23, viii. PubMed ID: 18295148
[TBL] [Abstract][Full Text] [Related]
17. Psychosis in a cocaine-dependent patient with ADHD during treatment with methylphenidate.
Delavenne H; Duarte Garcia F; Lacoste J; Cortese S; Charles-Nicolas A; Ballon N
Gen Hosp Psychiatry; 2013; 35(4):451.e7-9. PubMed ID: 22739113
[TBL] [Abstract][Full Text] [Related]
18. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature.
Wilens TE; Faraone SV; Biederman J; Gunawardene S
Pediatrics; 2003 Jan; 111(1):179-85. PubMed ID: 12509574
[TBL] [Abstract][Full Text] [Related]
19. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
20. Concomitant Drug Use among Opioid-Dependent Patients with and without Attention Deficit Hyperactivity Disorder: Does Methylphenidate Merit a Trial?
Tschudi L; Fischer SKM; Perlov E; Baumgartner MR; Soyka M; Müller TJ; Seifritz E; Mutschler J
Eur Addict Res; 2023; 29(5):305-312. PubMed ID: 37517394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
